Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles A B Boucher

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Current Opinion in Infectious Diseases|October 18, 2011
The potential for multidrug-resistant influenzaErhard van der Vries, Martin Schutten, Charles A B Boucher
Current Opinion in HIV and AIDS|April 18, 2009
HIV protease resistance and viral fitnessMonique Nijhuis, Noortje M van Maarseveen, Charles A B Boucher
Current Opinion in HIV and AIDS|December 22, 2017
Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategiesDavid A M C van de Vijver, Charles A B Boucher
The New England Journal of Medicine|October 1, 2010
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virusErhard van der Vries, Foekje F Stelma, Charles A B Boucher
Current Opinion in Infectious Diseases|September 18, 2010
The risk of HIV drug resistance following implementation of pre-exposure prophylaxisDavid A M C van de Vijver, Charles A B Boucher
Antiviral Therapy|January 25, 2013
Ongoing HIV replication in cerebrospinal fluid under successful monotherapyMarieke Bierhoff, Charles A B Boucher, Azzania Fibriani, et al.
AIDS (London, England)|June 29, 2016
Unite forces to validate biomarkers in the quest for lasting HIV remissionCasper Rokx, Stefano Vella, Guiseppe Pantaleo, et al.
Antiviral Therapy|May 29, 2008
Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretationsMark Mascolini, Douglas Richman, Brendan Larder, et al.
The Lancet. Infectious Diseases|April 28, 2017
Methodological concerns regarding a PrEP model - Authors' replyBrooke E Nichols, Charles A B Boucher, David A M van de Vijver
Journal of Acquired Immune Deficiency Syndromes (1999)|April 29, 2006
An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugsNoortje M van Maarseveen, Dorien de Jong, Charles A B Boucher, et al.
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Current Opinion in Infectious Diseases|October 18, 2011
The potential for multidrug-resistant influenzaErhard van der Vries, Martin Schutten, Charles A B Boucher
Current Opinion in HIV and AIDS|April 18, 2009
HIV protease resistance and viral fitnessMonique Nijhuis, Noortje M van Maarseveen, Charles A B Boucher
Current Opinion in HIV and AIDS|December 22, 2017
Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategiesDavid A M C van de Vijver, Charles A B Boucher
The New England Journal of Medicine|October 1, 2010
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virusErhard van der Vries, Foekje F Stelma, Charles A B Boucher
Current Opinion in Infectious Diseases|September 18, 2010
The risk of HIV drug resistance following implementation of pre-exposure prophylaxisDavid A M C van de Vijver, Charles A B Boucher
Antiviral Therapy|January 25, 2013
Ongoing HIV replication in cerebrospinal fluid under successful monotherapyMarieke Bierhoff, Charles A B Boucher, Azzania Fibriani, et al.
AIDS (London, England)|June 29, 2016
Unite forces to validate biomarkers in the quest for lasting HIV remissionCasper Rokx, Stefano Vella, Guiseppe Pantaleo, et al.
Antiviral Therapy|May 29, 2008
Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretationsMark Mascolini, Douglas Richman, Brendan Larder, et al.
The Lancet. Infectious Diseases|April 28, 2017
Methodological concerns regarding a PrEP model - Authors' replyBrooke E Nichols, Charles A B Boucher, David A M van de Vijver
Journal of Acquired Immune Deficiency Syndromes (1999)|April 29, 2006
An increase in viral replicative capacity drives the evolution of protease inhibitor-resistant human immunodeficiency virus type 1 in the absence of drugsNoortje M van Maarseveen, Dorien de Jong, Charles A B Boucher, et al.
Pageof 10